{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T10:27:10Z","timestamp":1789986430656,"version":"4.0.1"},"reference-count":35,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Revue des Maladies Respiratoires"],"published-print":{"date-parts":[[2023,10]]},"DOI":"10.1016\/j.rmr.2023.07.002","type":"journal-article","created":{"date-parts":[[2023,7,25]],"date-time":"2023-07-25T08:08:42Z","timestamp":1690272522000},"page":"684-691","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Les maladies oligom\u00e9tastatiques\u00a0: \u00e9tat actuel et perspectives dans les cancers bronchiques non \u00e0 petites cellules"],"prefix":"10.1016","volume":"40","author":[{"given":"T.","family":"Berghmans","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Brand\u00e3o","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.rmr.2023.07.002_bib0180","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.jtho.2015.09.009","article-title":"The IASLC lung cancer staging project: proposals for revision of the TNM Stage Groupings in the forthcoming (eighth) edition of the TNM classification for lung cancer","volume":"11","author":"Goldstraw","year":"2016","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.rmr.2023.07.002_bib0185","first-page":"2S292","article-title":"Co-morbidit\u00e9s et prise en charge des cancers bronchiques","volume":"2","author":"Berghmans","year":"2022","journal-title":"Rev Mal Respir Actual"},{"key":"10.1016\/j.rmr.2023.07.002_bib0190","first-page":"297","article-title":"The results of operations for the cure of cancer of the breast performed at the Johns Hopkins Hospital from June, 1889\u00a0to January, 1894","volume":"4","author":"Halsted","year":"1894","journal-title":"Johns Hopkins Bull"},{"key":"10.1016\/j.rmr.2023.07.002_bib0195","article-title":"Carcinoma of the breast, the unorthodox view","volume":"40","author":"Keynes","year":"1954","journal-title":"Proc Cardiff M Soc"},{"key":"10.1016\/j.rmr.2023.07.002_bib0200","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1200\/JCO.1995.13.1.8","article-title":"Oligometastases","volume":"13","author":"Hellman","year":"1995","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.rmr.2023.07.002_bib0205","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.1016\/j.jtho.2019.05.037","article-title":"Defining synchronous oligometastatic non-small cell lung cancer: a systematic review","volume":"14","author":"Giaj-Levra","year":"2019","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.rmr.2023.07.002_bib0210","doi-asserted-by":"crossref","first-page":"iv192","DOI":"10.1093\/annonc\/mdy275","article-title":"Metastatic non-small cell lung cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"29","author":"Planchard","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.rmr.2023.07.002_bib0215","doi-asserted-by":"crossref","first-page":"3473","DOI":"10.21037\/tlcr-20-964","article-title":"Current and future research efforts in oligometastatic non-small cell lung cancer-a systematic review","volume":"10","author":"Brand\u00e3o","year":"2021","journal-title":"Transl Lung Cancer Res"},{"key":"10.1016\/j.rmr.2023.07.002_bib0220","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1016\/j.jtho.2019.07.025","article-title":"Definition of synchronous oligometastatic non-small cell lung cancer-a consensus report","volume":"14","author":"Dingemans","year":"2019","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.rmr.2023.07.002_bib0225","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.ejca.2019.09.012","article-title":"EORTC Lung Cancer Group survey on the definition of NSCLC synchronous oligometastatic disease","volume":"122","author":"Levy","year":"2019","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.rmr.2023.07.002_bib0230","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.ejca.2019.09.013","article-title":"Defining oligometastatic non-small cell lung cancer: a simulated multidisciplinary expert opinion","volume":"123","author":"Hendriks","year":"2019","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.rmr.2023.07.002_bib0235","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1016\/S1470-2045(19)30718-1","article-title":"Characterisation and classification of oligometastatic disease: a European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus recommendation","volume":"21","author":"Guckenberger","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.rmr.2023.07.002_bib0240","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.lungcan.2013.07.026","article-title":"Is there an oligometastatic state in non-small cell lung cancer? A systematic review of the literature","volume":"82","author":"Ashworth","year":"2013","journal-title":"Lung Cancer"},{"key":"10.1016\/j.rmr.2023.07.002_bib0245","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/S0169-5002(02)00183-6","article-title":"A phase II trial of chemotherapy and surgery for non-small cell lung cancer patients with a synchronous solitary metastasis","volume":"38","author":"Downey","year":"2002","journal-title":"Lung Cancer"},{"key":"10.1016\/j.rmr.2023.07.002_bib0250","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.lungcan.2019.02.006","article-title":"Radical consolidative treatment provides a clinical benefit and long-term survival in patients with synchronous oligometastatic non-small cell lung cancer: a phase II study","volume":"130","author":"Arrieta","year":"2019","journal-title":"Lung Cancer"},{"key":"10.1016\/j.rmr.2023.07.002_bib0255","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.athoracsur.2014.01.052","article-title":"A prospective study of surgical procedures for patients with oligometastatic non-small cell lung cancer","volume":"98","author":"Endo","year":"2014","journal-title":"Ann Thorac Surg"},{"key":"10.1016\/j.rmr.2023.07.002_bib0260","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.1093\/annonc\/mdu370","article-title":"study of stereotactic body radiotherapy to primary tumor and metastatic locations in oligometastatic nonsmall-cell lung cancer patients","volume":"25","author":"Collen","year":"2014","journal-title":"Ann Oncol"},{"key":"10.1016\/j.rmr.2023.07.002_bib0265","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1097\/JTO.0b013e318262caf6","article-title":"Radical treatment of non-small-cell lung cancer patients with synchronous oligometastases: long-term results of a prospective phase II trial (Nct01282450)","volume":"7","author":"De Ruysscher","year":"2012","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.rmr.2023.07.002_bib0270","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.ijrobp.2018.06.400","article-title":"Long-Term outcomes of a phase 2\u00a0trial of chemotherapy with consolidative radiation therapy for oligometastatic non-small cell lung cancer","volume":"102","author":"Petty","year":"2018","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.rmr.2023.07.002_bib0275","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1016\/S1470-2045(16)30532-0","article-title":"Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2\u00a0study","volume":"17","author":"Gomez","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.rmr.2023.07.002_bib0280","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1200\/JCO.19.00201","article-title":"Local consolidative therapy vs. maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer: long-term results of a multi-institutional, phase II, randomized study","volume":"37","author":"Gomez","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.rmr.2023.07.002_bib0285","doi-asserted-by":"crossref","first-page":"e173501","DOI":"10.1001\/jamaoncol.2017.3501","article-title":"Consolidative radiotherapy for limited metastatic non-small-cell lung cancer: a phase 2\u00a0randomized clinical trial","volume":"4","author":"Iyengar","year":"2018","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.rmr.2023.07.002_bib0290","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1016\/S0140-6736(18)32487-5","article-title":"Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial","volume":"393","author":"Palma","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.rmr.2023.07.002_bib0295","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1093\/jnci\/djac015","article-title":"Randomized trial of first-line tyrosine kinase inhibitor with or without radiotherapy for synchronous Oligometastatic EGFR-Mutated NSCLC","volume":"115","author":"Wang","year":"2023","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.rmr.2023.07.002_bib0300","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1056\/NEJMoa1913662","article-title":"Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC","volume":"382","author":"Ramalingam","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.rmr.2023.07.002_bib0305","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.radonc.2018.07.017","article-title":"A cost-effectiveness analysis of consolidative local therapy in oligometastatic non-squamous non-small cell lung cancer (NSCLC)","volume":"129","author":"Panje","year":"2018","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.rmr.2023.07.002_bib0310","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa1504627","article-title":"Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer","volume":"373","author":"Brahmer","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.rmr.2023.07.002_bib0315","first-page":"2S45","article-title":"Immunoth\u00e9rapie et tumeurs oligom\u00e9tastatiques","volume":"12","author":"Berghmans","year":"2020","journal-title":"Rev Mal Respir Actual"},{"key":"10.1016\/j.rmr.2023.07.002_bib0320","doi-asserted-by":"crossref","first-page":"299","DOI":"10.2217\/imt-2017-0082","article-title":"Radiation therapy and immunotherapy: what is the optimal timing or sequencing?","volume":"10","author":"Aliru","year":"2018","journal-title":"Immunotherapy"},{"key":"10.1016\/j.rmr.2023.07.002_bib0325","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1001\/jamaoncol.2019.1449","article-title":"Pembrolizumab after completion of locally ablative therapy for oligometastatic non-small cell lung cancer: a phase 2\u00a0trial","volume":"5","author":"Bauml","year":"2019","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.rmr.2023.07.002_bib0330","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1200\/JCO.2017.77.0412","article-title":"Five-year follow-up of nivolumab in previously treated advanced non-small-cell lung cancer: results from the CA209-003\u00a0study","volume":"36","author":"Gettinger","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.rmr.2023.07.002_bib0335","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.22.01989","article-title":"Pembrolizumab plus pemetrexed and platinum in nonsquamous non-small-cell lung cancer: 5-year outcomes from the phase 3\u00a0KEYNOTE-189\u00a0study","author":"Garassino","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.rmr.2023.07.002_bib0340","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/S1470-2045(17)30230-9","article-title":"Prophylactic cranial irradiation versus observation in patients with extensive-disease small-cell lung cancer: a multicentre, randomised, open-label, phase 3\u00a0trial","volume":"18","author":"Takahashi","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.rmr.2023.07.002_bib0345","doi-asserted-by":"crossref","first-page":"3329","DOI":"10.21037\/tlcr-21-265","article-title":"Defining oligometastatic non-small cell lung cancer: concept versus biology, a literature review","volume":"10","author":"Mentink","year":"2021","journal-title":"Transl Lung Cancer Res"},{"key":"10.1016\/j.rmr.2023.07.002_bib0175","doi-asserted-by":"crossref","first-page":"ee020690","DOI":"10.1136\/bmjopen-2017-020690","article-title":"Study protocol for the SARON trial: a multicentre, randomised controlled phase III trial comparing the addition of stereotactic ablative radiotherapy and radical radiotherapy with standard chemotherapy alone for oligometastatic non-small cell lung cancer","volume":"8","author":"Conibear","year":"2018","journal-title":"BMJ Open"}],"container-title":["Revue des Maladies Respiratoires"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0761842523002048?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0761842523002048?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T14:24:28Z","timestamp":1760106268000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0761842523002048"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10]]},"references-count":35,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2023,10]]}},"alternative-id":["S0761842523002048"],"URL":"https:\/\/doi.org\/10.1016\/j.rmr.2023.07.002","relation":{},"ISSN":["0761-8425"],"issn-type":[{"value":"0761-8425","type":"print"}],"subject":[],"published":{"date-parts":[[2023,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Les maladies oligom\u00e9tastatiques\u00a0: \u00e9tat actuel et perspectives dans les cancers bronchiques non \u00e0 petites cellules","name":"articletitle","label":"Article Title"},{"value":"Revue des Maladies Respiratoires","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rmr.2023.07.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 SPLF. Published by Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}